The etiology of hypertension in the metabolic syndrome part one: An introduction to the history, the concept and the models

Current Vascular Pharmacology

Volumn 4, Issue 4, 2006, Pages 293-304

  Sharma, Vijay ^a   McNeill, John H ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Definition of metabolic syndrome; Epidemiology; Euglycemic hypeinsulinemic clamp; History; Homeostasis Model Assessment; Hyperinsulinemia; Hypertension; Insulin resistance; Insulin sensitivity; Metabolic syndrome; Obesity; Oral glucose tolerance test

Indexed keywords

CARBOXYPEPTIDASE H; DEOXYCORTICOSTERONE ACETATE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

CARDIOVASCULAR RISK; CLINICAL RESEARCH; CORONARY ARTERY DISEASE; DIAGNOSTIC PROCEDURE; HUMAN; HYPERINSULINEMIA; HYPERTENSION; INSULIN RESISTANCE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PATHOGENESIS; REVIEW; ANIMAL; CHEMICALLY INDUCED DISORDER; DISEASE MODEL; ENVIRONMENT; GENETICS; HYPERINSULINISM; MOUSE; PATHOPHYSIOLOGY; PHYSIOLOGY; RAT; RENOVASCULAR HYPERTENSION;

ANIMALS; DISEASE MODELS, ANIMAL; ENVIRONMENT; HUMANS; HYPERINSULINISM; HYPERTENSION; HYPERTENSION, RENAL; INSULIN RESISTANCE; METABOLIC SYNDROME X; MICE; OBESITY; RATS;

EID: 34249099674     PISSN: 15701611     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016106778521616     Document Type: Review

References (152)

1. Kahn R, Buse J, Ferrannini E, Stern M. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2005; 28(9): 2289-304.
2. Eknoyan G. On the central role of studies on the kidney in the recognition, conceptual evolution, and understanding of hypertension. Adv Chronic Kidney Dis 2004; 11(2): 192-6.
3. Ruskin A. Classics in arterial hypertension. Illinois: Springfield; 1956.
4. Naqvi NH, Blaufox MD. Blood pressure measurement: an illustrated history. New York: Parthenon Publishing; 1998.
5. Korotkov N. To the question of methods determining the blood pressure (from the clinic of Professor C.P. Federoof). Reports of the Imperial Military Academy 1905; 11: 365-367.
6. Hales S. An account of some hydraulic and hydrostatical experiments made on the blood and blood vessels of animals. London; 1733.
7. O'Brien E, Fitzgerald D. The history of blood pressure measurement. J Hum Hypertens 1994; 8(2): 73-84.
8. Fischer JW. The diagnostic value of the sphignomanometer in examinations for life insurance. JAMA 1914, 1752-1754.
9. Scholtz SB. Notes on arterial hypertension from an Amercian life insurance medicine viewpoint. In: Proceedings of the 2nd congress of life insurance physicians.; 1939; Paris, France; 1939.
10. Kannel WB. Bishop lecture. Contribution of the Framingham Study to preventive cardiology. J Am Coll Cardiol 1990; 15(1): 206-11.
11. The Framingham Study: DHEW Publication (NIH) December 1973.
12. Peitzman SJ. Bright's disease and Bright's generation-toward exact medicine at Guy's Hospital. Bull Hist Med 1981; 55(3): 307-21.
13. Traube L. Ueber den Zusammenhang vonHerz und Nierenkrankheiten. Berlin: Hirschwald; 1856.
14. Harlos J, Heidland A. Hypertension as cause and consequence of renal disease in the 19th century. Am J Nephrol 1994; 14(4-6): 436-42.
15. Cameron JS, Hicks J. Frederick Akbar Mahomed and his role in the description of hypertension at Guy's Hospital. Kidney Int 1996; 49(5): 1488-506.
16. Gordon DB. Hypertension. The renal basis. Stroudsberg, PA: Dowden, Hutchinson & Ross; 1980.
17. Goldblatt H, J JL, RFHanzel. Studies on experimental hypertension. The production of persistent elevation of systolic blood pressure by means of renal ischemia. J Exp Med 1934; 59: 347-79.
18. Page IH. The discovery of angiotensin. Perspect Biol Med 1975; 18(4): 456-62.
19. Guyton AC. Dominant role of the kidneys and accessory role of whole-body autoregulation in the pathogenesis of hypertension. Am J Hypertens 1989; 2(7): 575-85.
20. Ignarro LJ, Byrns RE, Buga GM, Wood KS, Chaudhuri G. Pharmacological evidence that endothelium-derived relaxing factor is nitric oxide: use of pyrogallol and superoxide dismutase to study endothelium-dependent and nitric oxide-elicited vascular smooth muscle relaxation. J Pharmacol Exp Ther 1988; 244(1): 181-9.
21. Moncada S, Radomski MW, Palmer RM. Endothelium-derived relaxing factor. Identification as nitric oxide and role in the control of vascular tone and platelet function. Biochem Pharmacol 1988; 37(13): 2495-501.
22. Panza JA, Quyyumi AA, Brush JE, Jr., Epstein SE. Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. N Engl J Med 1990; 323(1): 22-7.
23. Kylin E. Studien über das Hypertonie-Hyperglykämie- Hyperurikämiesyndrom. Zentrabl f innere Med Leipz 1923; 81: 105-27.
24. Vague J. La differentiation sexuelle, facteur determinant des formes de l'obesite. Presse Med 1947; 55: 339-340.
25. Vague J. La Differenciation Sexuelle Humaine. Paris: Masson; 1953.
26. Vague J. The degree of masculine differentiation of obesities: a factor determining predisposition to diabetes, atherosclerosis, gout, and uric calculous disease. Am J Clin Nutr 1956; 4(1): 20-34.
27. Vague J, Vague P, Jubelin J, Barre A. [Forms of obesity and metabolic disorders]. Verh Dtsch Ges Inn Med 1987; 93: 448-62.
28. Welborn TA, Breckenridge A, Rubinstein AH, Dollery CT, Fraser TR. Serum-insulin in essential hypertension and in peripheral vascular disease. Lancet 1966; 1(7451): 1336-7.
29. Welborn TA, Wearne K. Coronary heart disease incidence and cardiovascular mortality in Busselton with reference to glucose and insulin concentrations. Diabetes Care 1979; 2(2): 154-60.
30. Camus JP. [Gout, diabetes, hyperlipemia: a metabolic trisyndrome]. Rev Rhum Mal Osteoartic 1966; 33(1): 10-4.
31. Pyorala K. Relationship of glucose tolerance and plasma insulin to the incidence of coronary heart disease: results from two population studies in Finland. Diabetes Care 1979; 2(2): 131-41.
32. Modan M, Halkin H, Almog S, Lusky A, Eshkol A, Shefi M, et al. Hyperinsulinemia. A link between hypertension obesity and glucose intolerance. J Clin Invest 1985; 75(3): 809-17.
33. Modan M, Halkin H, Karasik A, Lusky A. Elevated serum uric acid-a facet of hyperinsulinaemia. Diabetologia 1987; 30(9): 713-8.
34. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988; 37(12): 1595-607.
35. Foster DW. Insulin resistance - a secret killer? N Engl J Med 1989; 320(11): 733-4.
36. DeFronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991; 14(3): 173-94.
37. Hwang IS, Ho H, Hoffman BB, Reaven GM. Fructose-induced insulin resistance and hypertension in rats. Hypertension 1987; 10(5): 512-6.
38. Reaven GM, Ho H, Hoffman BB. Attenuation of fructose-induced hypertension in rats by exercise training. Hypertension 1988; 12(2): 129-32.
39. Reaven GM, Ho H, Hoffmann BB. Somatostatin inhibition of fructose-induced hypertension. Hypertension 1989; 14(2): 117-20.
40. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001; 285(19): 2486-97.
41. Facchini F, Chen YD, Hollenbeck CB, Reaven GM. Relationship between resistance to insulin-mediated glucose uptake, urinary uric acid clearance, and plasma uric acid concentration. JAMA 1991; 266(21): 3008-11.
42. Juhan-Vague I, Thompson SG, Jespersen J. Involvement of the hemostatic system in the insulin resistance syndrome. A study of 1500 patients with angina pectoris. The ECAT Angina Pectoris Study Group. Arterioscler Thromb 1993; 13(12): 1865-73.
43. Chen NG, Holmes M, Reaven GM. Relationship between insulin resistance, soluble adhesion molecules, and mononuclear cell binding in healthy volunteers. J Clin Endocrinol Metab 1999; 84(10): 3485-9.
44. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998; 15(7): 539-53.
45. International Diabetes Federation consensus worldwide definition of the metabolic syndrome. In: International Diabetes Federation; 2005.
46. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005; 112(17): 2735-52.
47. Einhorn D, Reaven GM, Cobin RH, Ford E, Ganda OP, Handelsman Y, et al. American College of Endocrinology position statement on the insulin resistance syndrome. Endocr Pract 2003; 9(3): 237-52.
48. Laaksonen DE, Lakka HM, Niskanen LK, Kaplan GA, Salonen JT, Lakka TA. Metabolic syndrome and development of diabetes mellitus: application and validation of recently suggested definitions of the metabolic syndrome in a prospective cohort study. Am J Epidemiol 2002; 156(11): 1070-7.
49. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002; 288(21): 2709-16.
50. Grundy SM, Brewer HB, Jr., Cleeman JI, Smith SC, Jr., Lenfant C. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004; 109(3): 433-8.
51. Liao Y, Kwon S, Shaughnessy S, Wallace P, Hutto A, Jenkins AJ, et al. Critical evaluation of adult treatment panel III criteria in identifying insulin resistance with dyslipidemia. Diabetes Care 2004; 27(4): 978-83.
52. McLaughlin T, Abbasi F, Cheal K, Chu J, Lamendola C, Reaven G. Use of metabolic markers to identify overweight individuals who are insulin resistant. Ann Intern Med 2003; 139(10): 802-9.
53. Wang JJ, Hu G, Miettinen ME, Tuomilehto J. The metabolic syndrome and incident diabetes: assessment of four suggested definitions of the metabolic syndrome in a Chinese population with high post-prandial glucose. Horm Metab Res 2004; 36(10): 708-15.
54. Reaven GM. Insulin resistance, cardiovascular disease, and the metabolic syndrome: how well do the emperor's clothes fit? Diabetes Care 2004; 27(4): 1011-2.
55. Stern MP, Williams K, Gonzalez-Villalpando C, Hunt KJ, Haffner SM. Does the metabolic syndrome improve identification of individuals at risk of type 2 diabetes and/or cardiovascular disease? Diabetes Care 2004; 27(11): 2676-81.
56. Meigs JB, Cagliero E, Dubey A, Murphy-Sheehy P, Gildesgame C, Chueh H, et al. A controlled trial of web-based diabetes disease management: the MGH diabetes primary care improvement project. Diabetes Care 2003; 26(3): 750-7.
57. Haffner SM, Valdez RA, Hazuda HP, Mitchell BD, Morales PA, Stern MP. Prospective analysis of the insulin-resistance syndrome (syndrome X). Diabetes 1992; 41(6): 715-22.
58. He J, Klag MJ, Appel LJ, Charleston J, Whelton PK. Seven-year incidence of hypertension in a cohort of middle-aged African Americans and whites. Hypertension 1998; 31(5): 1130-5.
59. Mitchell BD, Haffner SM, Hazuda HP, Valdez R, Stern MP. The relation between serum insulin levels and 8-year changes in lipid, lipoprotein, and blood pressure levels. Am J Epidemiol 1992; 136(1): 12-22.
60. Evans M, McEwan P, Peters JR, Currie CJ. Should we routinely measure a proxy for insulin resistance as well as improve our modelling techniques to better predict the likelihood of coronary heart disease in people with type 2 diabetes? For debate. Diabetes Obes Metab 2004; 6(4): 299-307.
61. Smiley T, Oh P, Shane LG. The relationship of insulin resistance measured by reliable indexes to coronary artery disease risk factors and outcomes - a systematic review. Can J Cardiol 2001; 17(7): 797-805.
62. Yip J, Facchini FS, Reaven GM. Resistance to insulin-mediated glucose disposal as a predictor of cardiovascular disease. J Clin Endocrinol Metab 1998; 83(8): 2773-6.
63. Nosadini R, Manzato E, Solini A, Fioretto P, Brocco E, Zambon S, et al. Peripheral, rather than hepatic, insulin resistance and atherogenic lipoprotein phenotype predict cardiovascular complications in NIDDM. Eur J Clin Invest 1994;24(4):258-66.
64. Cordain L, Eades MR, Eades MD. Hyperinsulinemic diseases of civilization: more than just Syndrome X. Comp Biochem Physiol A Mol Integr Physiol 2003; 136(1): 95-112.
65. Ferrannini E. Hyperinsulinemia and insulin resistance. In: Olefsky JM, editor. Diabetes Mellitus. A Fundamental and Clinical Text. 3rd ed. Philadelphia, USA: Lippincott Williams & Wilkins; 2004. pp. 1457-1468.
66. Wilmsen HM, Ciaraldi TP, Carter L, Reehman N, Mudaliar SR, Henry RR. Thiazolidinediones upregulate impaired fatty acid uptake in skeletal muscle of type 2 diabetic subjects. Am J Physiol Endocrinol Metab 2003; 285(2): E354-62.
67. Ferrannini E, Balkau B. Insulin: in search of a syndrome. Diabet Med 2002; 19(9): 724-9.
68. Kirwan JP, Huston-Presley L, Kalhan SC, Catalano PM. Clinically useful estimates of insulin sensitivity during pregnancy: validation studies in women with normal glucose tolerance and gestational diabetes mellitus. Diabetes Care 2001; 24(9): 1602-7.
69. Stumvoll M, Mitrakou A, Pimenta W, Jenssen T, Yki-Jarvinen H, Van Haeften T, et al. Use of the oral glucose tolerance test to assess insulin release and insulin sensitivity. Diabetes Care 2000; 23(3): 295-301.
70. Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 1999; 22(9): 1462-70.
71. Gutt M, Davis CL, Spitzer SB, Llabre MM, Kumar M, Czarnecki EM, et al. Validation of the insulin sensitivity index (ISI(0,120)): comparison with other measures. Diabetes Res Clin Pract 2000;47(3):177-84.
72. Kanauchi M. A new index of insulin sensitivity obtained from the oral glucose tolerance test applicable to advanced type 2 diabetes. Diabetes Care 2002; 25(10): 1891-2.
73. DeFronzo RA. Lilly lecture 1987. The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM. Diabetes 1988; 37(6): 667-87.
74. Haffner SM, Ferrannini E, Hazuda HP, Stern MP. Clustering of cardiovascular risk factors in confirmed prehypertensive individuals. Hypertension 1992; 20(1): 38-45.
75. Skarfors ET, Lithell HO, Selinus I. Risk factors for the development of hypertension: a 10-year longitudinal study in middle-aged men. J Hypertens 1991; 9(3): 217-23.
76. Niskanen LK, Uusitupa MI, Pyorala K. The relationship of hyperinsulinaemia to the development of hypertension in type 2 diabetic patients and in non-diabetic subjects. J Hum Hypertens 1991; 5(3): 155-9.
77. Ferrannini E, Buzzigoli G, Bonadonna R, Giorico MA, Oleggini M, Graziadei L, et al. Insulin resistance in essential hypertension. N Engl J Med 1987; 317(6): 350-7.
78. Pollare T, Lithell H, Berne C. Insulin resistance is a characteristic feature of primary hypertension independent of obesity. Metabolism 1990; 39(2): 167-74.
79. Medalie JH, Papier CM, Goldbourt U, Herman JB. Major factors in the development of diabetes mellitus in 10,000 men. Arch Intern Med 1975; 135(6): 811-7.
80. Goff DC, Jr., Zaccaro DJ, Haffner SM, Saad MF. Insulin sensitivity and the risk of incident hypertension: insights from the Insulin Resistance Atherosclerosis Study. Diabetes Care 2003; 26(3): 805-9.
81. Fronzo RD, Bonnadonna R, Ferrannini E. Pathogenesis of non-insulin dependent diabetes mellitus. In: Alberti KGMM, Zimmet P, Fronzo RD, editors. International Textbook of Diabetes Mellitus. Chichester: Wiley; 1997. pp. 635-712.
82. Olefsky JM. Insulin resistance. In: Porte DJ, Sherwin RS, editors. Ellenberg & Rifkin's Diabetes Mellitus. USA: Appleton & Lange; 1997. pp. 513-552.
83. Kissebah AH, Krakower GR, Sonnenberg G, Hennes MMI. Clinical manifestations of the Metabolic Syndrome. In: Bray GA, Bouchard C, James CPT, editors. Handbook of Obesity. New York: Marcel Dekker; 1998. pp. 601-636.
84. Groop L, Lehto M, Orto M. Non-insulin dependent diabetes mellitus: a genetic and metabolic nightmare. Diabetes Nutr Metab 1994; 7: 253-261.
85. Jacob S, Machann J, Rett K, Brechtel K, Volk A, Renn W, et al. Association of increased intramyocellular lipid content with insulin resistance in lean nondiabetic offspring of type 2 diabetic subjects. Diabetes 1999;48(5):1113-9.
86. Pan DA, Lillioja S, Kriketos AD, Milner MR, Baur LA, Bogardus C, et al. Skeletal muscle triglyceride levels are inversely related to insulin action. Diabetes 1997; 46(6): 983-8.
87. Perseghin G, Scifo P, De Cobelli F, Pagliato E, Battezzati A, Arcelloni C, et al. Intramyocellular triglyceride content is a determinant of in vivo insulin resistance in humans: a 1H-13C nuclear magnetic resonance spectroscopy assessment in offspring of type 2 diabetic parents. Diabetes 1999; 48(8): 1600-6.
88. Phillips DI, Caddy S, Ilic V, Fielding BA, Frayn KN, Borthwick AC, et al. Intramuscular triglyceride and muscle insulin sensitivity: evidence for a relationship in nondiabetic subjects. Metabolism 1996; 45(8): 947-50.
89. Shafrir E, Sima AF. Animal Models of Diabetes: A Primer: Harwood Academic; 2000.
90. LeRoith D, Taylor SI, Olefsky JM. Diabetes Mellitus: A fundamental and clinical text. 3rd ed. Philadelphia: Lippincott Williams & Wilkins; 2004.
91. McNeill JH. Experimental Models of Diabetes. Danvers: CRC Press; 1999.
92. Ganten D, Jong Wd. Experimental and genetic models of hypertension: Elsevier; 1994.
93. Yagil Y, Yagil C. Genetic models of hypertension in experimental animals. Exp Nephrol 2001; 9(1): 1-9.
94. Rao RH. Insulin resistance in spontaneously hypertensive rats. Difference in interpretation based on insulin infusion rate or on plasma insulin in glucose clamp studies. Diabetes 1993; 42(9): 1364-71.
95. Iritani N, Fukuda E, Nara Y, Yamori Y. Lipid metabolism in spontaneously hypertensive rats (SHR). Atherosclerosis 1977; 28(3): 217-22.
96. O'Dowd BF, Rapp JP. Heterogeneity of renin alleles in outbred Dahl salt-sensitive (Brookhaven) rats. Hypertension 1991; 18(1): 9-11.
97. Sellye H. Production of nephrosclerosis by overdosage with deoxycortisone acetate. Can Med Assoc J 1942; 47: 515.
98. Schenk J, McNeill JH. The pathogenesis of DOCA-salt hypertension. J Pharmacol Toxicol Methods 1992; 27(3): 161-70.
99. Bursztyn M, Ben-Ishay D, Gutman A. Insulin resistance in spontaneously hypertensive rats but not in deoxycorticosterone-salt or renal vascular hypertension. J Hypertens 1992; 10(2): 137-42.
100. Zimmerman RS, Frohlich ED. Stress and hypertension. J Hypertens Suppl 1990; 8(4): S103-7.
101. Lin Q, Li P. Rostral medullary cholinergic mechanisms and chronic stress-induced hypertension. J Auton Nerv Syst 1990; 31(3): 211-7.
102. Iyer SN, Raizada MK, Katovich MJ. AT1 receptor density changes during development of hypertension in hyperinsulinemic rats. Clin Exp Hypertens 1996; 18(6): 793-810.
103. Smith PA, Graham LN, Mackintosh AF, Stoker JB, Mary DA. Sympathetic neural mechanisms in white-coat hypertension. J Am Coll Cardiol 2002; 40(1): 126-32.
104. Coste SC, Qi Y, Brooks VL, McCarron DA, Hatton DC. Captopril and stress-induced hypertension in the borderline hypertensive rat. J Hypertens 1995; 13(12 Pt 1): 1391-98.
105. Fregly MJ, Kikta DC, Threatte RM, Torres JL, Barney CC. Development of hypertension in rats during chronic exposure to cold. J Appl Physiol 1989; 66(2): 741-9.
106. Sun ZJ, Zhang ZE. Historic perspectives and recent advances in major animal models of hypertension. Acta Pharmacol Sin 2005; 26(3): 295-301.
107. Dai S, Todd ME, Lee S, McNeill JH. Fructose loading induces cardiovascular and metabolic changes in nondiabetic and diabetic rats. Can J Physiol Pharmacol 1994; 72(7): 771-81.
108. Verma S, Bhanot S, McNeill JH. Sympathectomy prevents fructose-induced hyperinsulinemia and hypertension. Eur J Pharmacol 1999; 373(2-3): R1-4.
109. Verma S, Bhanot S, McNeill JH. Antihypertensive effects of metformin in fructose-fed hyperinsulinemic, hypertensive rats. J Pharmacol Exp Ther 1994; 271(3): 1334-7.
110. Verma S, Bhanot S, Yao L, McNeill JH. Defective endothelium-dependent relaxation in fructose-hypertensive rats. Am J Hypertens 1996; 9(4 Pt 1): 370-6.
111. Pierce GN, Lockwood MK, Eckhert CD. Cardiac contracile protein ATPase activity in a diet induced model of noninsulin dependent diabetes mellitus. Can J Cardiol 1989; 5(2): 117-20.
112. Huang BW, Chiang MT, Yao HT, Chiang W. The effect of high-fat and high-fructose diets on glucose tolerance and plasma lipid and leptin levels in rats. Diabetes Obes Metab 2004; 6(2): 120-6.
113. Hall JE. Pathophysiology of obesity hypertension. Curr Hypertens Rep 2000; 2(2): 139-47.
114. Carey RM, Siragy HM. Newly recognized components of the renin-angiotensin system: potential roles in cardiovascular and renal regulation. Endocr Rev 2003; 24(3): 261-71.
115. da Silva AA, Kuo JJ, Tallam LS, Hall JE. Role of endothelin-1 in blood pressure regulation in a rat model of visceral obesity and hypertension. Hypertension 2004; 43(2): 383-7.
116. Roberts CK, Vaziri ND, Wang XQ, Barnard RJ. Enhanced NO inactivation and hypertension induced by a high-fat, refined-carbohydrate diet. Hypertension 2000; 36(3): 423-9.
117. Barnard RJ, Faria DJ, Menges JE, Martin DA. Effects of a high-fat, sucrose diet on serum insulin and related atherosclerotic risk factors in rats. Atherosclerosis 1993; 100(2): 229-36.
118. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature 1994; 372(6505): 425-32.
119. Lee GH, Proenca R, Montez JM, Carroll KM, Darvishzadeh JG, Lee JI, et al. Abnormal splicing of the leptin receptor in diabetic mice. Nature 1996; 379(6566): 632-5.
120. Chen H, Charlat O, Tartaglia LA, Woolf EA, Weng X, Ellis SJ, et al. Evidence that the diabetes gene encodes the leptin receptor: identification of a mutation in the leptin receptor gene in db/db mice. Cell 1996; 84(3): 491-5.
121. Chua SC, Jr., Chung WK, Wu-Peng XS, Zhang Y, Liu SM, Tartaglia L, et al. Phenotypes of mouse diabetes and rat fatty due to mutations in the OB (leptin) receptor. Science 1996; 271(5251): 994-6.
122. Klebig ML, Wilkinson JE, Geisler JG, Woychik RP. Ectopic expression of the agouti gene in transgenic mice causes obesity, features of type II diabetes, and yellow fur. Proc Natl Acad Sci USA 1995; 92(11): 4728-32.
123. Lu D, Willard D, Patel IR, Kadwell S, Overton L, Kost T, et al. Agouti protein is an antagonist of the melanocyte-stimulating-hormone receptor. Nature 1994; 371(6500): 799-802.
124. Noben-Trauth K, Naggert JK, North MA, Nishina PM. A candidate gene for the mouse mutation tubby. Nature 1996; 380(6574): 534-8.
125. Kleyn PW, Fan W, Kovats SG, Lee JJ, Pulido JC, Wu Y, et al. Identification and characterization of the mouse obesity gene tubby: a member of a novel gene family. Cell 1996; 85(2): 281-90.
126. Naggert JK, Fricker LD, Varlamov O, Nishina PM, Rouille Y, Steiner DF, et al. Hyperproinsulinaemia in obese fat/fat mice associated with a carboxypeptidase E mutation which reduces enzyme activity. Nat Genet 1995; 10(2): 135-42.
127. Cool DR, Normant E, Shen F, Chen HC, Pannell L, Zhang Y, et al. Carboxypeptidase E is a regulated secretory pathway sorting receptor: genetic obliteration leads to endocrine disorders in Cpe(fat) mice. Cell 1997; 88(1): 73-83.
128. Chua SC, Jr., White DW, Wu-Peng XS, Liu SM, Okada N, Kershaw EE, et al. Phenotype of fatty due to Gln269Pro mutation in the leptin receptor (Lepr). Diabetes 1996; 45(8): 1141-3.
129. Iida M, Murakami T, Ishida K, Mizuno A, Kuwajima M, Shima K. Phenotype-linked amino acid alteration in leptin receptor cDNA from Zucker fatty (fa/fa) rat. Biochem Biophys Res Commun 1996; 222(1): 19-26.
130. Bray GA, York DA. Studies on food intake of genetically obese rats. Am J Physiol 1972; 223(1): 176-9.
131. Zucker TF, Zucker LM. Hereditary obesity in the rat associated with high serum fat and cholesterol. Proc Soc Exp Biol Med 1962; 110: 165.
132. Ionescu E, Sauter JF, Jeanrenaud B. Abnormal oral glucose tolerance in genetically obese (fa/fa) rats. Am J Physiol 1985; 248(5 Pt 1): E500-6.
133. Zucker LM, Antoniades HN. Insulin and obesity in the Zucker genetically obese rat "fatty". Endocrinology 1972; 90(5): 1320-30.
134. Peterson RG, Shaw WN, Neel M, Little L, Eichberg J. Zucker diabetic fatty rat as a model for noninsulin-dependent diabetes mellitus. ILAR News 1990; 32: 16.
135. Reitman ML. Rodent genetic models of obesity and type 2 diabetes. In: Roith DLL, Taylor SI, Olefsky JM, editors. Diabetes mellitus. A fundamental and clinical text. 3rd ed. Philadelphia: Lippincott Williams and Wilkins; 2004. pp. 1041-58.
136. Goto Y, Suzuki K, Ono T, Sasaki M, Toyota T. Development of diabetes in the non-obese NIDDM rat (GK rat). Adv Exp Med Biol 1988; 246: 29-31.
137. Kawano K, Hirashima T, Mori S, Saitoh Y, Kurosumi M, Natori T. Spontaneous long-term hyperglycemic rat with diabetic complications. Otsuka Long-Evans Tokushima Fatty (OLETF) strain. Diabetes 1992; 41(11): 1422-8.
138. Shinohara M, Masuyama T, Shoda T, Takahashi T, Katsuda Y, Komeda K, et al. A new spontaneously diabetic non-obese Torii rat strain with severe ocular complications. Int J Exp Diabetes Res 2000; 1(2): 89-100.
139. Bielschowsky M, Goodall CM. Origin of inbred NZ mouse strains. Cancer Res 1970; 30(3): 834-6.
140. Hansen BC. Primate animal models of type 2 diabetes. In: Olefsky JM, editor. Diabetes mellitus. A fundamental and clinical text. 3rd ed. Philadelphia: Lippincott Williams and Wilkins; 2004. pp. 1059-1074.
141. Leiter EH, Reifsnyder PC, Flurkey K, Partke HJ, Junger E, Herberg L. NIDDM genes in mice: deleterious synergism by both parental genomes contributes to diabetogenic thresholds. Diabetes 1998; 47(8): 1287-95.
142. Hirayama I, Yi Z, Izumi S, Arai I, Suzuki W, Nagamachi Y, et al. Genetic analysis of obese diabetes in the TSOD mouse. Diabetes 1999; 48(5): 1183-91.
143. Ueda H, Ikegami H, Yamato E, Fu J, Fukuda M, Shen G, et al. The NSY mouse: a new animal model of spontaneous NIDDM with moderate obesity. Diabetologia 1995; 38(5): 503-8.
144. Kim JH, Sen S, Avery CS, Simpson E, Chandler P, Nishina PM, et al. Genetic analysis of a new mouse model for non-insulin-dependent diabetes. Genomics 2001; 74(3): 273-86.
145. Walkley SU, Hunt CE, Clements RS, Lindsey JR. Description of obesity in the PBB/Ld mouse. J Lipid Res 1978; 19(3): 335-41.
146. Frankel BJ. Diabetes in the Chinese Hamster. In: Shafrir E, editor. Lessons from animal diabetes. Boston: Birkhauser; 1996. pp. 267-298.
147. Voss KM, Herberg L, Kern HF. Fine structural studies of the islets of langerhans in the Djungarian hamster (Phodopus sungorus). Cell Tissue Res 1978; 191(2): 333-42.
148. Bell RH, Jr., Hye RJ. Animal models of diabetes mellitus: physiology and pathology. J Surg Res 1983; 35(5): 433-60.
149. Kalderon B, Gutman A, Levy E, Shafrir E, Adler JH. Characterization of stages in development of obesity-diabetes syndrome in sand rat (Psammomys obesus). Diabetes 1986; 35(6): 717-24.
150. Shafrir E, Adler JH. Enzymatic and metabolic responses to affluent diet of two diabetes-prone species of spiny mice: Acomys cahirinus and Acomys russatus. Int J Biochem 1983; 15(12): 1439-46.
151. Wise PH, Weir BJ, Hime JM, Forrest E. Implications of hyperglycaemia and cataract in a colony of tuco-tucos (Ctenomys talarum). Nature 1968; 219(161): 1374-6.
152. Abiola O, Angel JM, Avner P, Bachmanov AA, Belknap JK, Bennett B, et al. The nature and identification of quantitative trait loci: a community's view. Nat Rev Genet 2003; 4(11): 911-6.